U.S. Coronary Artery Bypass Grafts Market Revenue & Forecast Analysis
The U.S. coronary artery bypass grafts market was evaluated at USD 9.0 billion in 2025 and is projected to grow at a CAGR of 3.2% from USD 9.3 billion in 2026 to USD 12.4 billion in 2035. The robust market growth is mainly influenced by the widespread occurrence of coronary artery disease (CAD), the rising number of bypass surgeries, and the expanding elderly population vulnerable to cardiovascular issues. Furthermore, improvements in surgical methods, increased utilisation of minimally invasive and off-pump CABG procedures, along with a robust cardiac care infrastructure, are fostering market expansion.
Market Overview
The National Heart, Lung, and Blood Institute states that over 300,000 coronary artery bypass graft (CABG) surgeries occur each year in the United States, indicating ongoing demand for coronary artery bypass grafts and associated cardiac surgical products.
The U.S. coronary artery bypass grafts (CABG) market has expanded consistently over time, driven by the rising incidence of coronary artery disease, an increase in cardiac surgeries, and a heightened need for efficient revascularization methods. The growth of specialized heart centers, progress in surgical methods, and enhanced post-operative results have also bolstered market expansion. For instance, in 2024, Edwards Lifesciences Corporation enhanced its cardiovascular surgery offerings, promoting the progress of cardiac surgical techniques throughout the United States.
The U.S. coronary artery bypass grafts market is projected to experience significant growth in the forecast period due to the rising incidence of cardiovascular diseases, an expanding elderly population, and ongoing innovations in minimally invasive and robotic-assisted cardiac surgical technologies. The growing need for intricate coronary revascularization surgeries and heightened funding in advanced cardiac care facilities are additionally facilitating market growth. for instance, by 2035, the uptake of advanced surgical technologies and cardiovascular solutions from companies like Medtronic plc is anticipated to grow substantially in U.S. hospitals and cardiac centers, fueled by the demand for enhanced surgical accuracy and better patient results.
U.S. Coronary Artery Bypass Grafts Market Overview
Base Year Market Size (2025): USD 9.0 Billion
CAGR: 3.2%
Forecast Year Market Size (2035): USD 12.7 Billion
Major Players:
Abbott Laboratories
Edwards Lifesciences Corporation
Getinge AB (Maquet Cardiovascular)
Johnson & Johnson MedTech
Medtronic plc.
U.S. Coronary Artery Bypass Grafts Market Trends
The U.S. coronary artery bypass grafts market is experiencing notable progress due to the rising prevalence of coronary artery disease, greater embrace of advanced cardiac surgical methods, and ongoing innovations in cardiovascular treatment.
The increasing use of minimally invasive and off-pump CABG techniques is enhancing patient results by decreasing surgical stress, reducing hospital durations, and speeding up recovery periods.
The rising application of arterial grafts, especially internal mammary artery grafts, is boosting long-term graft patency and elevating the success rates of coronary revascularization techniques.
Innovations in robotic-assisted heart surgery and intraoperative imaging technologies are enhancing surgical accuracy and boosting process efficiency.
Moreover, hospitals are progressively allocating resources towards hybrid operating rooms and sophisticated cardiovascular surgery facilities to facilitate intricate cardiac procedures and enhance patient treatment.
Collectively, these technological developments and the increasing need for efficient coronary revascularization methods are anticipated to propel the sustained growth of the U.S. coronary artery bypass grafts market.
U.S. Coronary Artery Bypass Grafts Market Analysis
By Method
Off-pump CABG dominates the U.S. coronary artery bypass grafts market due to its ability to reduce procedure-related complications and recovery time
Based on the method, the U.S. coronary artery bypass grafts market is categorized into off-pump, on-pump, and minimally invasive direct CABG (MIDCAB). The off-pump segment leads the market with the highest market share of 63.40% in 2025.
By Surgical Procedure
Triple CABG surgery dominates the U.S. coronary artery bypass grafts market due to the high prevalence of three-vessel coronary artery disease requiring comprehensive revascularisation
Based on the surgical procedure, the U.S. coronary artery bypass grafts market is categorized into single CABG surgery, double CABG surgery, triple CABG surgery, quadruple CABG surgery, and quintuple bypass. The triple CABG surgery segment leads the market with the highest market share in 2025.
By Age Group
The 55–69 years age group dominates the U.S. coronary artery bypass grafts market due to the high incidence of advanced coronary artery disease in this population
Based on the age group, the U.S. coronary artery bypass grafts market is categorized into <40 years, 40–54 years, 55–69 years, and 70 years and above. The 55–69 years segment leads the market with the highest market share in 2025.
By End-use
Hospitals dominate the U.S. coronary artery bypass grafts market owing to their advanced cardiac surgery infrastructure and high procedural volumes
Based on the end-use, the U.S. coronary artery bypass grafts market is categorized into hospitals, cardiology centers, and others. The hospitals segment leads the market with the highest market share in 2025.
Key Companies Profiled
The U.S. coronary artery bypass grafts market features a competitive environment with prominent cardiovascular device manufacturers and cardiac surgery solution providers vying through technological advancements, strategic partnerships, and the growth of their cardiovascular offerings. Leading firms like Abbott Laboratories, Edwards Lifesciences Corporation, Getinge AB, Johnson & Johnson MedTech, and Medtronic plc possess substantial market shares owing to their robust involvement in cardiac surgery technologies, surgical instruments, and cardiovascular care solutions.
The market continues to be very competitive, as companies concentrate on minimally invasive CABG methods, robotic surgery systems, vessel harvesting innovations, and sophisticated cardiac operating room solutions to enhance their market standing. Heightened investments in heart disease research, escalating need for intricate coronary revascularization operations, and the expanding use of cutting-edge surgical technologies are amplifying competition. Furthermore, strategic collaborations with hospitals and specialized cardiac centers persist in fostering market growth and innovation throughout the U.S. coronary artery bypass grafts market.
U.S. Coronary Artery Bypass Grafts Market Companies:
Abbott Laboratories
Artivion, Inc.
Baxter International Inc.
Becton, Dickinson and Company (BD)
Edwards Lifesciences Corporation
Getinge AB
Johnson & Johnson MedTech
LeMaitre Vascular, Inc.
LivaNova PLC
Medtronic plc
Meril Life Sciences Pvt. Ltd.
MicroPort Scientific Corporation
Terumo Corporation
Teleflex Incorporated
W. L. Gore & Associates, Inc.
Market Segmentation
This study provides revenue growth and emerging trends across global, regional, and country levels from 2021 to 2035, segmenting the U.S. coronary artery bypass graft market by-
Method (Revenue in USD Million, 2021 - 2035)
Off-pump
On-pump
Minimally Invasive Direct CABG (MIDCAB)
Surgical Procedure (Revenue in USD Million, 2021 - 2035)
Single CABG Surgery
Double CABG Surgery
Triple CABG Surgery
Quadruple CABG Surgery
Quintuple bypass
Age Group (Revenue in USD Million, 2021 – 2035)
<40 years
40–54 years
55–69 years
70 years and above
End-use (Revenue in USD Million, 2021 – 2035)
Hospitals
Cardiology Centers
Others
Table of Content
1. Methodology and Scope
1.1. Scope of the Study
1.1.1. Market Segmentation
1.1.2. Market Definition
1.1.3. Inclusions and Exclusions of the Study
1.2. Research Design
1.2.1. Base Year, Historical Data, and Forecast Period
1.2.2. Data Collection Methods
1.2.2.1. Secondary Sources
1.2.2.2. Primary Sources
1.2.3. Research Methodology
1.2.3.1. Base Year Calculation/ Parent Market Analysis, Company/ Brand Share Analysis, 2025 (Top-down Approach)
1.2.3.2. Volume-Price Approach (Bottom-up Approach)
1.2.3.3. Data Triangulation
1.2.4. Forecasting Model
1.3. Research Assumptions
1.4. Validation and Data Quality Control
1.5. List of Primary Sources
1.6. List of Secondary Sources
2. Executive Summary
2.1. Market Overview
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
3. Industry Outlook
3.1. Industry Ecosystem Analysis
3.2. Parent/ Ancillary Market Analysis
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Restraints/ Challenges
3.3.3. Opportunities
3.4. Value Chain Analysis
3.5. Technology Roadmap
3.6. Porters Analysis
3.7. PESTLE Analysis
4. Market Estimates and Forecasts, By Method, 2021 - 2035 (Market Size in USD Bn)
4.1. Off-pump
4.2. On-pump
4.3. Minimally Invasive Direct CABG (MIDCAB)
5. Market Estimates and Forecasts, By Surgical Procedure, 2021 – 2035 (USD Bn)
5.1. Single CABG Surgery
5.2. Double CABG Surgery
5.3. Triple CABG Surgery
5.4. Quadruple CABG Surgery
5.5. Quintuple bypass
6. Market Estimates and Forecasts, By Age Group, 2021 – 2035 (USD Bn)
6.1. <40 years
6.2. 40–54 years
6.3. 55–69 years
6.4. 70 years and above
7. Market Estimates and Forecasts, By End-use, 2021 – 2035 (USD Bn)
7.1. Hospitals
7.2. Cardiology Centers
7.3. Others
8. Market Estimates and Forecasts, By U.S., 2021 - 2035 (USD Mn)
8.1.1. U.S.
8.1.1.1. U.S. Coronary Artery Bypass Graft Market Estimates and Forecasts to 2035 (USD Mn)
8.1.1.2. Market Dynamics
8.1.1.3. Competitive Landscape
8.1.1.4. Regulatory Framework
8.1.1.5. Reimbursement Scenario
9. Competitive Landscape
9.1. Company Market Share Analysis, 2024
9.2. Company Tier Structure
9.3. List of Major Suppliers, By Key Countries
9.4. Key Company Positioning Analysis
9.5. Company Profile
9.5.1. Abbott Laboratories
9.5.2. Artivion, Inc.
9.5.3. Baxter International Inc.
9.5.4. Becton, Dickinson and Company (BD)
9.5.5. Edwards Lifesciences Corporation
9.5.6. Getinge AB
9.5.7. Johnson & Johnson MedTech
9.5.8. LeMaitre Vascular, Inc.
9.5.9. LivaNova PLC
9.5.10. Medtronic plc
9.5.11. Meril Life Sciences Pvt. Ltd.
9.5.12. MicroPort Scientific Corporation
9.5.13. Terumo Corporation
9.5.14. Teleflex Incorporated
9.5.15. W. L. Gore & Associates, Inc.
10. Analyst Perspective
11. Related Reports
Related Research
Revolution Insights Briefs
Stay informed with updates on related market reports and key industry topics.